[Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate].
Five cases of myelodysplastic syndrome were treated with cytarabine ocfosfate. Ocfosfate (100-200 mg) was orally administered for 14 days with 14 days' interval. Etoposide was combined in one case, and nartograstim was added in two cases. Two of the five cases achieved remission, one case having complete remission, and another case showing a good response. Their remission durations were 141 and 112 days, respectively. Further improvement of therapy is needed to achieve a higher remission rate and a longer remission duration.
Nishi
T
T
Dept. of Internal Medicine, Wakayama Medical College Kihoku Hospital.
Funasako
M
M
Hata
N
N
Andoh
K
K
Itoh
Y
Y
Ono
H
H
Itoh
K
K
Sato
Y
Y
Sato
H
H
Taniji
M
M
Nakai
S
S
Ueda
A
A
Fujimoto
H
H
Ohata
M
M
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001088:Arabinonucleotides / Q000008:administration & dosage*; D003568:Cytidine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D012074:Remission Induction
D000970:Antineoplastic Agents; D001088:Arabinonucleotides; D016179:Granulocyte Colony-Stimulating Factor; C061162:1-arabinofuranosylcytosine-5'-stearylphosphate; D005047:Etoposide; D003568:Cytidine Monophosphate; C072115:nartograstim